Joining Medtronic are Ardian’s three existing investors: Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners, as well as new investor Emergent Medical Partners.
Andrew Cleeland, president and CEO of Ardian, said: “We are thrilled to have attracted this strong team of investors and appreciate the confidence they have shown in funding the development of this clinically important technology.
“We are particularly encouraged to have Medtronic as a new partner, and see their investment as a validation of our exceptional early clinical results, as well as the potential of our treatment for such a pervasive and complex disease.”